Jeffrey Weber

Title: Jeffrey Weber: Innovator in Melanoma Treatment

Introduction

Jeffrey Weber is a notable inventor based in New York, NY (US), recognized for his contributions to cancer treatment. He has developed a significant patent that aims to improve patient outcomes in melanoma therapy. His work focuses on predicting the response of cancer patients to immune checkpoint inhibitors, which are crucial in modern oncology.

Latest Patents

Weber holds a patent titled "Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods." This innovative method involves analyzing mass spectrometry data from blood samples to predict how well patients will respond to specific antibody drugs. By utilizing a classifier that compares integrated intensity values with a training set of mass spectral data, Weber's method can classify patients as likely to benefit more or less from the treatment.

Career Highlights

Jeffrey Weber is currently associated with Biodesix, Inc., where he continues to advance research in cancer diagnostics and treatment. His work has the potential to significantly impact the way melanoma is treated, providing personalized medicine solutions for patients.

Collaborations

Weber collaborates with talented professionals in his field, including Joanna Röder and Krista Meyer. Their combined expertise contributes to the innovative research and development efforts at Biodesix, Inc.

Conclusion

Jeffrey Weber's contributions to melanoma treatment through his patented methods exemplify the importance of innovation in healthcare. His work not only enhances the understanding of patient responses to treatment but also paves the way for more effective cancer therapies.